Skip to main content
Premium Trial:

Request an Annual Quote

Settlement on Allegedly Faked COVID-19 Results

A Los Angeles-based company that allegedly provided faked coronavirus testing results is to pay more $20 million in a settlement, the Los Angeles Times reports.

It adds that prosecutors alleged that the company, Sameday Technologies, told hundreds of patients they tested negative for COVID-19 when it actually had not run the samples. Los Angeles City Attorney Mike Feuer and District Attorney George Gascón further alleged that the company forged results at the direction of CEO Felix Huettenbach when people complained that their results were not returned in a timely manner, the LA Times says, adding that this allegedly affected about 500 results.

"In the early days, amidst the chaos of massive surges in demand for services, and shortages in supplies, we failed to meet the standards for excellence our customers deserve," Sameday says in a statement, according to the LA Times, adding that it has "corrected the problems."

During the COVID-19 pandemic, testing laboratories have faced delays in shipping, leading testing and reference labs to adopt a range of transportation approaches, as 360Dx reported in 2021.

The LA Times adds that an ad from Sameday says it has "nailed the logistics of [sample transportation] down so in most of our locations it's less than 24 hours."

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.